Nirsevimab (YTE Mutant)

Nirsevimab, also known as MEDI8897, is a recombinant neutralizing monoclonal antibody developed against human respiratory syncytial virus (RSV). It is an IgG1kappa antibody, that has a triple mutation in the Fc region designed to increase its serum half-life. The YTE (M252Y/S254T/T256E) mutation increases the binding of the antibody to the FcRn n(eonatal Fc receptor) at acidic pH, enhancing the receptor mediated recycling and extending its circulation. Nirsevimab, also known as MEDI8897, is a recombinant neutralizing monoclonal antibody developed against human respiratory syncytial virus (RSV). It is an IgG1kappa antibody, that has a triple mutation in the Fc region designed to increase its serum half-life. The YTE (M252Y/S254T/T256E) mutation increases the binding of the antibody to the FcRn (neonatal Fc receptor) at acidic pH, enhancing the receptor mediated recycling and extending its circulation. Due to that characteristic it allows the use of one single injection for the whole of the RSV season. RSV is a common viral respiratory disease, being most prevalent in children under 2 years of age. While it is tends not to be serious, it can result in pneumonia. The development of antibodies such as nirsevimab are thus highly beneficial.